Top AI companies in Tel Aviv

Gauzy (NASDAQ:GAUZ) is a global leader in Smart Glass and ADAS technologies, focused on the research, development, manufacturing, and marketing of vision and light control technologies and systems. We believe in innovation that matters. By making materials that do more, we reimagine how we interact with our surroundings and the spaces we spend our time most through light, and the control of it. Through direct fulfillment and a certified distribution channel spanning over 40 countries, Gauzy serves leading brands in automotive, transportation, aeronautics, architecture, consumer goods, medical devices, and beyond. Joining the Gauzy team means being part of an elite group of innovators with a passion for creating groundbreaking products that shape our everyday lives. At Gauzy, we value hard work, unique ideas, collaboration, and cultural diversity. Gauzy has 14 offices globally and over 600 employees. Comprised of four distinct business units– Gauzy Automotive, Gauzy Architecture, Gauzy Aeronautics, and Gauzy Safety Tech – we offer a wide range of career paths to achieve your professional goals. To apply for a position at Gauzy, visit gauzy.com/careers To speak with a sales representative at Gauzy, visit gauzy.com/contact

• Post-IPO equity
• 154 employees
• Founded 2009

What is Ximus?The name Ximus drives from the Latin word Eximius which means extraordinary or exemplary. Forum Ximus is a closed community of peers, a platform where exceptional people can harness the knowledge, influence, and experience of Israel’s most innovative business leaders to inspire professional, personal and social growth.Ximus will foster its community around a series of invitation-only events that will bring inspiring content and unique adventures to breathtaking venues, giving our members the opportunity to have mind-opening discussions and form lasting relationships with one another.

• 146 employees
• Founded 2018

INSS (The Institute for National Security Studies) is an independent academic institute that studies key issues relating to Israel's national security and Middle East affairs. Through its mixture of researchers with backgrounds in academia, the military, government, and public policy, INSS is able to contribute to the public debate and governmental deliberation of leading strategic issues and offer policy analysis and recommendations to decision makers and public leaders, policy analysts, and theoreticians, both in Israel and abroad. As part of its mission, it is committed to encourage new ways of thinking and expand the traditional contours of establishment analysis. Conceiving of security studies as a dynamic interdisciplinary field that involves military, intellectual, economic, and social resources, the Institute strives to reflect that diversity and complexity through research and policy recommendations of the highest standard. Complementing the traditional areas of defense, security doctrine, and politics, INSS has expanded its focus to include the “softer” components of national security, such as domestic trends and social processes. The Institute is non-partisan, independent, and autonomous in its fields of research and expressed opinions. As an external institute of Tel Aviv University, it maintains a strong association with the academic environment. In addition, it has a strong association with the political and military establishment.

• 139 employees
• Founded 2006

Founded in 1996, the International Institute for Counter-Terrorism (ICT) is one of the leading academic institute for counter-terrorism in the world, facilitating international cooperation in the global struggle against terrorism. ICT is an independent think tank providing expertise in terrorism, counter-terrorism, homeland security, threat vulnerability and risk assessment, intelligence analysis and national security and defense policy.

• 137 employees
• Founded 1996

About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (UnigenTM) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned potential best-in-class Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's offices are located in Israel. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN

• Post-IPO equity
• 113 employees
• Founded 1993